       Document 0067
 DOCN  M9610067
 TI    Myocardial atrophy in acquired immunodeficiency syndrome--associated
       wasting.
 DT    9601
 AU    Samaan SA; Foster A; Raizada V; Schade DS; Koster F; Crawford MH;
       Department of Internal Medicine, University of New Mexico Health;
       Sciences Center, Albuquerque 87131, USA.
 SO    Am Heart J. 1995 Oct;130(4):823-7. Unique Identifier : AIDSLINE
       MED/96021220
 AB    This study evaluated the effects of acquired immunodeficiency syndrome
       wasting syndrome (AWS) on the heart in a population free of overt
       opportunistic infection or clinical evidence of cardiac disease. Data
       from 53 patients with AWS and 16 healthy age-matched controls were
       studied. By echocardiography, a significant reduction in left
       ventricular mass was found in patients with AWS that remained
       significantly reduced when corrected for body surface area. Mean
       ejection fraction was within the normal range in patients with AWS but
       was significantly less than in controls. End-systolic volume index was
       slightly elevated in patients with AWS. Although no difference in
       end-systolic wall stress was seen, the end-systolic wall
       stress-shortening relation differed significantly. These findings are
       consistent with myocardial atrophy and subtle left ventricular
       dysfunction in patients with AWS.
 DE    Acquired Immunodeficiency Syndrome/PATHOLOGY/*PHYSIOPATHOLOGY  Adult
       Age Factors  Atrophy  Body Surface Area
       Cachexia/*ETIOLOGY/PHYSIOPATHOLOGY  CD4 Lymphocyte Count
       Echocardiography  Heart/*PHYSIOPATHOLOGY  Human  Male  Matched-Pair
       Analysis  Myocardium/*PATHOLOGY  Stroke Volume  Support, Non-U.S. Gov't
       Support, U.S. Gov't, P.H.S.  Ventricular Dysfunction, Left  JOURNAL
       ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

